<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2301221622
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2022
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Pulmirema 1 mg
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        BUDESONIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        0.5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Inhalation use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Nebuliser suspension
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        191.30
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Cipla Limited " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Cipla Limited 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2272]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SUDAIR PHARMA COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SUDAIR PHARMA COMPANY
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        R03BA02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>PULMIREMA Nebuliser Suspension contain a medicine called budesonide. This belongs to a group of medicines called &lsquo;corticosteroids&rsquo;. It works by reducing and preventing swelling and inflammation in your lungs.</p><p>&nbsp;</p><p>PULMIREMA Nebuliser Suspension are used to control and prevent asthma symptoms in children ages 12 months to 8 years.</p><p>&nbsp;</p><p><strong>PULMIREMA Nebuliser Suspension </strong><strong>does not treat the sudden symptoms (wheezing, cough, shortness of breath, and chest pain or tightness) of an asthma attack. Always have a short-acting beta<sub>2</sub>-agonist medicine (rescue inhaler) with you to treat sudden symptoms. If your child does not have an inhaled, short-acting bronchodilator, ask your healthcare provider to have one prescribed for your child. </strong></p><p>&nbsp;</p><p>It is not known if PULMIREMA Nebuliser Suspension are safe or effective in children younger than 12 months or older than 8 years.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use </strong><strong>PULMIREMA Nebuliser Suspension </strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you or your child are allergic to budesonide or any of the ingredients of this medicine (listed in section 6).</p><p>&nbsp;</p><p><strong>Warnings and precautions </strong></p><p>Talk to your doctor or pharmacist before using PULMIREMANebuliser Suspension, tell your doctor or pharmacist if you or your child:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; has or recently had chicken pox or measles, or has recently been near anyone with chicken pox or measles.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; has or had tuberculosis of the respiratory tract.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; has certain kinds of infections that have not been treated, including:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fungal infections</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bacterial infections</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; viral infections</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; parasitic infections</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; herpes simplex infection of the eye (ocular herpes simplex)</p><p>PULMIREMA Nebuliser Suspension may not be right for children who have had any of these types of infections.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; has decreased bone mineral density (bone strength). Your child is at risk for decreased bone mineral density if he or she:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; is inactive for a long period of time</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; has a family history of osteoporosis</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; does not eat well (poor nutrition)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; takes bone thinning medicines (such as anticonvulsant medicines or corticosteroids) for a long time.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; has an eye problem such as increased pressure in the eye, glaucoma or cataracts.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; has liver problems</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; is planning to have surgery.</p><p>&nbsp;</p><p><strong>Other medicines and </strong><strong>PULMIREMA Nebuliser Suspension </strong></p><p>Tell your doctor or pharmacist if you or your child are taking, recently taken or might take any other medicines. This includes medicines that you buy without a prescription and herbal medicines.</p><p>&nbsp;</p><p>In particular, tell your doctor or pharmacist if you or your child are taking of the following medicines:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Corticosteroids</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anti-seizure medicine (anticonvulsants)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines that suppress the immune system (immunosuppressant)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines to treat fungal infections (such as ketoconazole)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Certain medicines that can affect how your liver breaks down medicine</p><p>&nbsp;</p><p>Ask your doctor or pharmacist for a list of these medicines, if you are not sure.</p><p>&nbsp;</p><p>Know the medicines your child takes. Keep a list of them and show it to your doctor and pharmacist when your child gets a new medicine.</p><p>&nbsp;</p><p><strong>Pregnancy, breast-feeding and fertility </strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine - do not use PULMIREMA Nebuliser Suspension unless your doctor tells you to.</p><p>&nbsp;</p><p>PULMIREMA Nebuliser Suspension may not be right for women who is pregnant or plans to become pregnant. It is not known if PULMIREMA Nebuliser Suspension will harm your unborn baby.</p><p>&nbsp;</p><p>PULMIREMA Nebuliser Suspension may not be right for women who is breast-feeding or plans to breast-feed. PULMIREMA Nebuliser Suspension can pass into breast milk. You and your doctor should decide if you will use PULMIREMA Nebuliser Suspension or breast-feed.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>PULMIREMA Nebuliser Suspension are not likely to affect you being able to drive or use any tools or machines.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PULMIREMA Nebuliser Suspension comes in three strengths. Your doctor has prescribed the strength that is best for your child.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PULMIREMA Nebuliser Suspension is for inhaled use only.&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not mix PULMIREMA Nebuliser Suspension with other nebulizer medicines. If you child uses another medicine by inhalation to treat asthma, talk with your doctor for instructions on when to use the other medicine.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Improvement in the control of asthma symptoms with PULMIREMA Nebuliser Suspension can occur within 2-8 days. It may take up to 4-6 weeks before maximum improvement is seen.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Make sure your child always has a short-acting beta<sub>2</sub>-agonist medicine with him or her. Your child should use the short-acting beta<sub>2</sub>-agonist medicine for breathing problems between doses of PULMIREMA Nebuliser Suspension or if a sudden asthma attack happens. Call your doctor right away if:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the short-acting rescue medicine does not work as well for relieving asthma symptoms.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; your child needs to use the short-acting rescue medicines more often than usual.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; your child&rsquo;s breathing problems worsen with PULMIREMA Nebuliser Suspension</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rinse your child&rsquo;s mouth with water and have him or her spit the water out after each PULMIREMA Nebuliser Suspension treatment. Do not swallow the water. This will lessen the chance of getting a fungal infection (thrush) in the mouth.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your child has used long-term corticosteroids and the dose is now being lowered or stopped, a warning card should be carried stating that your child may need corticosteroids during times of stress or during an asthma attack that does not get better with bronchodilator medicines.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor may check your child&rsquo;s blood, breathing and do eye exams while using PULMIREMA Nebuliser Suspension.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Read <strong>Instructions for Use</strong> as below about how to use PULMIREMA Nebuliser Suspension.</p><p>&nbsp;</p><p><strong><u>Instruction for use</u></strong></p><p><strong>&nbsp;</strong></p><p>PULMIREMA Nebuliser Suspension is only for use with a jet nebulizer machine. Make sure you know how to use your jet nebulizer machine before your child uses PULMIREMA Nebuliser Suspension.</p><p>&nbsp;</p><p>PULMIREMA Nebuliser Suspension is a liquid that is turned into a mist by a nebulizer and inhaled into the lungs.</p><p>&nbsp;</p><p>The face mask should be properly adjusted to optimize delivery and to avoid exposing the eyes to the nebulized medication. Corticosteroid effects on the skin can be avoided if the face is washed after the use of a face mask.</p><p><strong>&nbsp;</strong></p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PULMIREMA Nebuliser Suspension come in a sealed protective aluminum foil envelope.</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not open the sealed pouch until you are ready to use a dose of PULMIREMA Nebuliser Suspension.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Open the sealed foil envelope along the dotted line and take out 1 single-dose ampule from the strip. See Figure 1.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Record the date that you opened the foil on the back of the envelope in the space provided.</p><p>&nbsp;</p><p>1.&nbsp; &nbsp; Return the unopened PULMIREMA ampules on the strip back into the foil envelope before storing.</p><p><img alt="" width="119" height="113" src="data:image/png;base64,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" /></p><p>&nbsp;</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gently shake the PULMIREMA ampule using a circular motion as shown in Figure 2.</p><p><img alt="" width="123" height="125" src="data:image/png;base64,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" /></p><p>&nbsp;</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hold the PULMIREMA ampule upright without squeezing the ampule and open by twisting off the top as shown in Figure 3.</p><p><img alt="" width="112" height="117" src="data:image/png;base64,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" /></p><p>&nbsp;</p><p>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Place the open end of the PULMIREMA ampule into the nebulizer cup (reservoir) and slowly squeeze all of the medicine from the ampule into the nebulizer medicine cup as shown in Figure 4. Throw away the empty ampule.</p><p><img alt="" width="113" height="122" src="data:image/png;base64,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" /></p><p>&nbsp;</p><p>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Use your jet nebulizer as directed.</p><p>&nbsp;</p><p><strong>If you use more </strong><strong>PULMIREMA Nebuliser Suspension </strong><strong>than you should </strong></p><p>It is important that you take your dose as stated on the pharmacist&rsquo;s label or as advised by your doctor. You should not increase or decrease your dose without seeking medical advice. If you use more PULMIREMA Nebuliser Suspension than you should, contact your doctor or pharmacist for advice.</p><p>&nbsp;</p><p><strong>If you stop using </strong><strong>PULMIREMA Nebuliser Suspension </strong></p><p>Do not stop using PULMIREMA Nebuliser Suspension, and do not change your child&rsquo;s dose of PULMIREMA Nebuliser Suspension without talking to your doctor.</p><p>&nbsp;</p><p><strong>If you forget to use PULMIREMA Nebuliser Suspension</strong></p><p>If you forget to take a dose, skip the missed dose and take the next dose as usual.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>If either of the following happen to you, stop using </strong><strong>PULMIREMA Nebuliser Suspension</strong><strong> and talk to your doctor immediately:</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Thrush (<em>candida</em>), a fungal infection in your mouth and throat. Tell your healthcare provider if your child has any redness or white coloured patches in the mouth or throat.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Worsening of asthma or sudden asthma attacks.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic reactions. Tell your doctor or get medical help right away if your child has:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin rash, redness or swelling</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe itching</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of the face, mouth and tongue</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; trouble breathing or swallowing</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chest pain</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anxiety (feeling of doom)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Immune system effects and a higher chance of infections. Your child is more likely to get infections when taking medicines that weaken the immune system. Symptoms of infection may include: fever, pain, aches, chills, feeling tired, nausea and vomiting. Tell your doctor about any signs of infection while your child uses PULMIREMA Nebuliser Suspension.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adrenal insufficiency. Adrenal insufficiency is a condition in which the adrenal glands do not make enough steroid hormones. Symptoms of adrenal insufficiency include tiredness, weakness, nausea and vomiting, and low blood pressure.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decrease in bone mineral density (bone strength). Your healthcare provider may want to check your child for this during treatment with PULMIREMA Nebuliser Suspension.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Slowed or delayed growth problems. Your child&rsquo;s healthcare provider may want to monitor your child&rsquo;s growth while using PULMIREMA Nebuliser Suspension.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Eye problems, including glaucoma (increased pressure in the eye) and cataracts (clouding of the lens in the eye). Your child&rsquo;s healthcare provider may suggest eye exams while using PULMIREMA Nebuliser Suspension.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Increased wheezing right after taking </strong><strong>PULMIREMA Nebuliser Suspension</strong><strong>. Always have a fast-acting inhaled bronchodilator medicine with you to treat sudden wheezing. </strong></p><p>&nbsp;</p><p><strong>Other possible side effects:</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; respiratory infections. Symptoms may include stuffy nose, sore nose and throat.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; runny nose</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cough</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; viral infections</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; viral irritation and inflammation of the stomach and intestine (gastroenteritis). Gastroenteritis symptoms may include: stomach area pain, diarrhea, nausea and vomiting, and loss of appetite.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ear infections</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nosebleed</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pink eye (conjunctivitis)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash</p><p>&nbsp;</p><p>Tell your doctor if your child has any side effect that bothers him or her or that does not go away.</p><p>&nbsp;</p><p><strong>Reporting of side effects </strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the local reporting system. By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not store above 30&deg;C, protect from light, do not freeze.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep this medicine out of the sight and reach of children.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine after the expiry date which is stated on the label and carton after EXP. The expiry date refers to the last day of that month.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; After opening Do not store above 30&deg;C, do not freeze.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The open envelope can used within 3 months.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What </strong><strong>PULMIREMA Nebuliser Suspension</strong><strong> </strong><strong>contains</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is PULMIREMA. Each respule of 2 mL suspension contains 0.25 mg, 0.5mg and 1mg budesonide USP.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are polysorbate 80, sodium chloride, edetate disodium, sodium citrate, citric acid monohydrate and water for injection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What PULMIREMA Nebuliser Suspension look like and contents of the pack
This medicine are white to off white homogenous redispersible suspension filled in 2 ml FFS respules on visual examination.

Carton containing 6 combipack having 5 respules of 2 ml each.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Manufactured by </strong></p><p>Cipla Ltd, Unit l, Plot 9, 10 &amp; 15, Indore Special Economic Zone, Phase-ll, Pithampur, District- Dhar, Madhya Pradesh, India &ndash; 454775 (henceforth termed as &ldquo;Cipla Indore&rdquo;)</p><p>&nbsp;</p><p><strong>MARKETING AUTHORISATION Holder </strong></p><p>Sudair Pharma Company (SPC)</p><p>King Fahad road, Building 8006- 4<sup>th</sup> floor - Riyadh, Saudi Arabia</p><p>Tel: +966-11-920001432</p><p>Fax: +966-11-4668195</p><p>Email: info@sudairpharma.com</p><p>Mailing: P.O. Box 19047 Riyadh, Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Leaflet Revised: 
April 2021

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي<strong> </strong>بلميريما معلق للاستخدام في جهاز الاستنشاق على مادة تُسمى بوديسونيد. ينتمي هذا الدواء إلى مجموعة من الأدوية تُعرف باسم &quot;الكورتيكوستيرويدات&quot;. يعمل هذا الدواء على تقليل والوقاية من تورم الرئتين والتهابها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُستخدم بلميريما معلق للاستخدام في جهاز الاستنشاق للسيطرة على أعراض مرض الربو وللوقاية منها لدى المرضى من الأطفال ممن تتراوح أعمارهم من 12 شهر إلى 8 سنوات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>بلميريما</strong> <strong>معلق للاستخدام في جهاز الاستنشاق غير مُخصص لعلاج الأعراض المفاجئة لنوبة الربو مثل </strong><strong>(</strong><strong>أزيز الصدر &quot;صفير عند التنفس&quot; وسعال وضيق في التنفس وألم أو ضيق بالصدر</strong><strong>).&nbsp; </strong><strong>احرص دائمًا على اصطحاب أدوية مناهضات</strong><strong>&nbsp;</strong><strong>بيتا </strong><strong>2&nbsp;</strong><strong>قصيرة المفعول</strong><strong>&nbsp;(</strong><strong>دواء الاستنشاق الإنقاذي</strong><strong>) </strong><strong>معك لعلاج أعراض الربو المفاجئة</strong><strong>.</strong><strong> إذا لم يكن لدى طفلك أدوية استنشاقية موسعة للشعب الهوائية قصيرة المفعول، فاطلب من مقدم الرعاية الصحية الخاص بك وصفها لطفلك</strong><strong>.&nbsp; </strong></p><p dir="RTL">من غير المعروف ما إذا كان بلميريما معلق للاستخدام في جهاز الاستنشاق أمن أو فعّال في الأطفال الذين تقل أعمارهم عن 12 شهر أو أكبر من 8 سنوات أم لا.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>يحظر استخدام بلميريما معلق للاستخدام في جهاز الاستنشاق في الحالات التالية</strong><strong>: </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني أنت أو طفلك من حساسية تجاه بوديسونيد أو تجاه أي مكون من المكونات الأخرى الداخلة في تركيب هذا الدَّواء (المدرجة بالقسم رقم 6).&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong> <strong>&nbsp;</strong></p><p dir="RTL">استشر الطبيب المعالج لك أو الصيدلي الخاص بك قبل استخدام بلميريما معلق للاستخدام في جهاز الاستنشاق إذا تعرضت أنت أو طفلك من أيِ من الحالات التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني أو قد عانيت مؤخرًا من جدري الماء أو الحصبة أو إذا اختلطت مؤخرًا بأي شخص مُصاب بالجدري أو الحصبة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني أو قد عانيت من الإصابة بمرض السل بالجهاز التنفسي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من بعض أنواع العدوى التي لا يمكن علاجها مثل:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالات العدوى الفطرية.&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالات العدوى البكتيرية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالات العدوى الفيروسية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالات العدوى الطفيلية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالات عدوى الهربس البسيط بالعين (هربس العين البسيط).</p><p dir="RTL">بلميريما معلق للاستخدام في جهاز الاستنشاق قد لا يكون مناسبًا للأطفال الذين قد أُصيبوا بأيِ نوع من أنواع هذه العدوى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من انخفاض الكثافة المعدنية&nbsp;للعظم (قوة العظام). إذا كان طفلك معرض لمخاطر انخفاض الكثافة المعدنية&nbsp;للعظم لأيِ سبب من الأسباب التالية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة عدم التحرك أو ممارسة أي نشاط لفترة طويلة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة وجود تاريخ مرضي عائلي من الاصابة بهشاشة العظام.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة عدم التغذية والأكل بشكل جيد (سوء التغذية).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناول أدوية لعلاج ضعف العظام (مثل أدوية مضادات&nbsp;التشنج أو الكورتيكوستيرويدات) لفترة طويلة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشاكل بالعين مثل ارتفاع الضغط داخل العين أو الجلوكوما &quot;المياه الزرقاء&quot; أو الكاتاراكت &quot;اعتمام عدسة العين&quot;.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشاكل بالكبد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت على وشك الخضوع لعملية جراحية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>استعمال بلميريما معلق للاستخدام في جهاز الاستنشاق</strong><strong> مع الأدوية الأخرى: </strong></p><p dir="RTL">أخبر الطبيب المعالج لك أو الصيدلي الخاص بك إذا كنت تتناول أنت أو طفلك أو تناولتم مؤخرًا أو قد تتناولون أي أدوية أخرى. ويشمل ذلك تلك الأدوية التي حصلتِ عليها دون وصفة طبية والأدوية العشبية.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">وعلى وجه الخصوص، أخبر الطبيب المعالج لك أو الصيدلي الخاص بك إذا كنت تتناول أنت أو طفلك أيًّ من الأدوية التَّالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الكورتيكوستيرويدات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المعالجة للنوبات التشنجية (مضادات التشنج).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تعمل على تثبيط الجهاز المناعي (مثبطات المناعة).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تُستخدم لعلاج حالات العدوى الفطرية (مثل كيتوكونازول)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض الأدوية التي قد تؤثر على طريقة تفتيت الكبد للدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يرجى استشارة الطبيب المعالج لك أو الصيدلي الخاص بك حول قائمة هذه الأدوية، إذا كنت غير متأكدًا من هذ الأمر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تعرف أولًا على الأدوية التي يتناولها طفلك. احتفظ بقائمة هذه الادوية واعرضها على الطبيب المعالج لك أو الصيدلي الخاص بك عندما يتم وصف دواء جديد لطفلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرَّضاعة الطبيعية والخصوبة</strong> <strong>&nbsp;</strong></p><p dir="RTL">إذا كنتِ حاملًا أو تمارسين الرضاعة الطبيعية أو تعتقدين أنكِ قد تكونين حاملاً أو تخططين للحمل، فاستشيري الطبيب المعالج لكِ أو الصيدلي الخاص بكِ للحصول على النصيحة قبل استخدام هذا الدَّواء. لا تستخدمي بلميريما معلق للاستخدام في جهاز الاستنشاق إلا إذا أخبركِ الطبيب المعالج لكِ بذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بلميريما معلق للاستخدام في جهاز الاستنشاق قد لا يكون مناسبًا للسيدات الحوامل أو اللاتي يُخططن للحمل. من غير المعروف ما إذا كان بلميريما معلق للاستخدام في جهاز الاستنشاق يُسبب ضررًا للجنين أم لا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بلميريما معلق للاستخدام في جهاز الاستنشاق قد لا يكون مناسبًا للسيدات اللاتي يمارسن الرضاعة الطبيعية أو يُخططن لممارسة الرضاعة الطبيعية. يمكن أن يُفرز بلميريما معلق للاستخدام في جهاز الاستنشاق في لبن الأم. يجب أن تقرري أنتِ والطبيب المعالج لكِ ما إذا كنتِ تنوين استخدام بلميريما معلق للاستخدام في جهاز الاستنشاق أو ممارسة الرضاعة الطبيعية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قيادة السيارات واستخدام الآلات</strong><strong>:</strong></p><p dir="RTL">من غير المُحتمَل أن يؤثر<strong> </strong>بلميريما معلق للاستخدام في جهاز<strong> </strong>الاستنشاق على قدرتك على قيادة السيارات أو استخدام أي أدوات أو آلات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; استخدم هذا الدَّواء تمامًا كما أخبرك الطبيب المعالج لك أو الصيدلي الخاص بك. يُرجى التحدث مع الطبيب المعالج لك أو الصيدلي الخاص بك إذا لم تكن متأكدًا من كيفية الاستعمال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يتوفر بلميريما معلق للاستخدام في جهاز الاستنشاق بثلاثة تركيزات. سيقوم الطبيب المعالج لك بوصف التركيز الأنسب لك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بلميريما معلق للاستخدام في جهاز الاستنشاق مٌخصص للاستخدام عن طريق الاستنشاق فقط.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تقم بخلط بلميريما معلق للاستخدام في جهاز الاستنشاق مع غيره من الأدوية الأخرى التي تستخدم داخل أجهزة الاستنشاق. إذا كان طفلك يستخدم دواء آخر للاستنشاق لعلاج الربو، فتحدث إلى الطبيب المعالج لك للحصول على تعليمات بشأن متى يجب استخدام الدواء الأخر.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكن أن يعمل بلميريما معلق للاستخدام في جهاز الاستنشاق على التحكم والسيطرة على الاعراض الناجمة عن مرض الربو في غضون مدة تتراوح من 2 إلى 8 أيام. قد يستغرق هذا الأمر مدة تتراوح من 4 إلى 6 أسابيع حتى الوصول إلى التحسن التام في حالتك المرضية.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تأكد أن طفلك يصطحب معه أو معها دائمًا أدوية مناهضات&nbsp;بيتا-2 قصيرة المفعول. يجب أن يستخدم طفلك أدوية مناهضات&nbsp;ب بيتا-2 قصيرة المفعول لعلاج مشاكل التنفس، وتُستخدم بين فترات تلقي جرعات بلميريما معلق للاستخدام في جهاز الاستنشاق أو عند حدوث نوبات ربو مفاجئة. اتصل بالطبيب المعالج لك فورًا في الحالات التَّالية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا يعمل دواء الاستنشاق الإنقاذي قصير المفعول على تخفيف حدة أعراض الربو.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحتاج طفلك إلى استخدام دواء الاستنشاق الإنقاذي قصير المفعول عدد مرات أكثر من المعتاد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سوف تزداد مشاكل التنفس لدى طفلك سوءً مع استخدام بلميريما معلق للاستخدام في جهاز الاستنشاق أم لا.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اغسل فم طفلك بالماء واجعله يٌخرج الماء بعد كل مرة من تلقي علاج بلميريما معلق للاستخدام في جهاز الاستنشاق. لا تجعله يبلع الماء، حيث سيقلل ذلك من فرص الإصابة بعدوى فطرية (السُلاق) في الفم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أستخدم طفلك الكورتيكوستيرويدات لفترة طويلة ويتم الآن تقليل أو وقف الجرعة الخاصة به، يجب اصطحاب بطاقة تنبيهية معك تفيد أن طفلك قد يحتاج إلى الكورتيكوستيرويدات عند التعرض لمشاكل بالتنفس أو عند الإصابة بنوبات ربو لا يمكن علاجها عن طريق الأدوية الموسعة للشعب الهوائية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يحتاج الطبيب المعالج لطفلك إلى إجراء فحوصات للدم والتنفس والعين لدى طفلك أثناء استخدام بلميريما معلق للاستخدام في جهاز الاستنشاق.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;يُرجى <strong>قراءة تعليمات الاستخدام</strong> المُوضحة أدناه بشأن استخدام بلميريما معلق للاستخدام في جهاز الاستنشاق.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>تعليمات الاستخدام:</u></strong></p><p dir="RTL">بلميريما معلق للاستخدام في جهاز الاستنشاق يستعمل فقط مع أجهزة الاستنشاق الدافعة. تأكد من أنك تعرف جيدًا كيفية استخدام أجهزة الاستنشاق الدافعة قبل أن يستخدم طفلك بلميريما معلق للاستخدام في جهاز الاستنشاق.&nbsp;&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">بلميريما معلق للاستخدام في جهاز الاستنشاق عبارة عن سائل يتحول إلى بخار عن طريق جهاز الاستنشاق ويمر البخار المستنشق إلى الرئتين.&nbsp;&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب ضبط وضع قناع الوجه بشكل صحيح، بحيث يتم إحكامه على الأنف لتلقي العلاج، تجنبًا تعرض العين للدواء المستنشق. يمكن تجنب تأثيرات الكورتيكوستيرويدات على الجلد، إذا تم غسل الوجه عقب استخدام قناع جهاز الاستنشاق.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">1.&nbsp;&nbsp; بلميريما معلق للاستخدام في جهاز الاستنشاق يتوفر في عبوة مغلفة بطبقة واقية من رقائق الألومنيوم محكمة الإغلاق.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تقم بفتح العبوة المغلقة إلا إذا كنت مستعدًا لاستعمال جرعة بلميريما معلق للاستخدام في جهاز الاستنشاق.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; افتح شريط إغلاق غلاف رقائق الألومنيوم بطول الخط المنقط وأخرج من الشريط أمبول يحتوي على جرعة واحدة، انظر الشكل رقم 1.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سجل التاريخ الذي قمت فيه بفتح شريط إغلاق غلاف رقائق الألومنيوم على ظهر الغلاف في المساحة المخصصة لذلك.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">1.&nbsp;&nbsp; أعد أمبولات بلميريما غير المفتوحة إلى الشريط مرة أخرى في غلاف رقائق الألومنيوم قبل الحفظ.</p><p><img alt="" width="119" height="113" src="data:image/png;base64,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" /></p><p>&nbsp;</p><p dir="RTL">2.&nbsp; &nbsp; &nbsp;قم بتحريك أمبول بلميريما برفق باستخدام حركة دائرية كما هو موضح في الشكل رقم 2.</p><p dir="RTL"><img alt="" width="123" height="125" src="data:image/png;base64,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" /></p><p dir="RTL">&nbsp;</p><p dir="RTL">3.&nbsp;&nbsp; أمسك أمبول بلميريما في وضع مستقيم دون الضغط على الأمبول وافتحها عن طريق لف الجزء العلوي من الأمبول كما هو موضح في الشكل رقم 3.</p><p dir="RTL"><img alt="" width="112" height="117" src="data:image/png;base64,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" /></p><p dir="RTL">&nbsp;</p><p dir="RTL">4.&nbsp;&nbsp; ضع الطرف المفتوح لأمبول بلميريما في وعاء جهاز الاستنشاق (الجزء المخصص للدواء) واضغط ببطء لإخراج الدواء من الأمبول إلى وعاء بخاخ الدواء كما هو موضح في الشكل رقم 4.&nbsp; تخلص من الأمبول الفارغ.</p><p dir="RTL"><img alt="" width="113" height="122" src="data:image/png;base64,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" /></p><p dir="RTL">&nbsp;</p><p dir="RTL">5.&nbsp;&nbsp; استخدم جهاز الاستنشاق الدافع حسب التعليمات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا استخدمت كمية أكثر مما يجب من بلميريما معلق للاستخدام في جهاز الاستنشاق:</strong></p><p dir="RTL">من المهم أن تتناول جرعتك كما حددها ملصق الصيدلي الخاص بك أو كما وصفها الطبيب المعالج لك. يحظر عليك زيادة أو تقليل الجرعة الخاصة بك دون الحصول أولًا على استشارة طبية بشأن هذا الأمر. إذا استخدمت جرعة أكثر مما يجب من بلميريما معلق للاستخدام في جهاز الاستنشاق، اتصل بالطبيب المعالج لك أو الصيدلي الخاص للحصول على النصيحة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن استعمال بلميريما معلق للاستخدام في جهاز الاستنشاق</strong></p><p dir="RTL">لا تتوقف عن استخدام بلميريما معلق للاستخدام في جهاز الاستنشاق ولا تقم بتغيير جرعة طفلك من بلميريما معلق للاستخدام في جهاز الاستنشاق دون استشارة الطبيب المعالج له.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا نسيت استعمال بلميريما معلق للاستخدام في جهاز الاستنشاق:</strong></p><p dir="RTL">إذا نسيت استخدام أي جرعة من الدواء، فتجاوز الجرعة التي نسيتها واستخدم الجرعة التالية على النحو المعتاد.</p><p dir="RTL">إذا كانت لديك أية أسئلة إضافية حول استخدام هذا الدَّواء، فاستشر الطبيب المعالج لك أو الصيدلي الخاص بك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">قد يُسبب هذا الدواء، مثله مثل كافة الأدوية، آثارًا جانبية على الرغم من عدم حدوثها لجميع المرضى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>توقف عن استعمال</strong> <strong>بلميريما معلق للاستخدام في جهاز الاستنشاق، وتحدث إلى الطبيب المعالج لك فورًا،</strong> <strong>إذا تعرضت للإصابة بأي أثر من الآثار الجانبية التالية:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض السُلَاقً (عدوى بداء&nbsp;المبيضات)، وهي عدوى فطرية بالفم والحلق. أخبر مقدم الرعاية الصحية الخاص بك إذا كان طفلك يعاني من الإصابة بوجود أي بقع حمراء أو بيضاء بالفم أو الحلق.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاقم أعراض مرض الربو أو نوبات ربو مفاجئة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات حساسية: اتصل بالطبيب المعالج لك أو احصل على المساعدة الطبية في الحال إذا كان طفلك يعاني مما يلي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي أو احمرار أو تورم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة شديدة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورُّم بالوجه والفم واللسان.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في التنفُّس أو البلع.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالصدر</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قلق (شعور بالغضب الشديد).&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تأثيرات على الجهاز المناعي وفرصة مرتفعة للإصابة بحالات العدوى: إذا كان طفلك يتناوُل أدوية تُضعف من جهازه المناعي، فهو مُعرَّض بشكل أكبر للإصابة بحالات العدوى. قد تشمل أعراض العدوى ما يلي: حُمى وألم ووجع وقشعريرة وشعور بالتعب وغثيان وقيئ. أخبر الطبيب المعالج بأي علامات للعدوى تظهر علي الطفل أثناء استعماله بلميريما معلق للاستخدام في جهاز الاستنشاق.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قصور بالغدة الكظرية: يعتبر قصور الغدة الكظرية حالة لا تفرز فيها الغدد الكظرية كمية كافية من الهرمونات الستيرويدية. تشتمل أعراض قصور الغدة الكظرية على تعب وضعف وغثيان وقيئ وانخفاض ضغط الدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص في كثافة المعادن بالعظام (قوة العظام): من الممكن أن يقرر مقدم الرعاية الصحية الخاص بك فحص طفلك من أجل ذلك أثناء العلاج باستعمال بلميريما معلق للاستخدام في جهاز الاستنشاق.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل تباطؤ أو تأخر النمو: من الممكن أن يقرر مقدم الرعاية الصحية الخاص بك متابعة نمو طفلك أثناء استعمال بلميريما معلق للاستخدام في جهاز الاستنشاق.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشمل مشاكل العين على الإصابة بمرض المياه الزرقاء (الجلوكوما) (زيادة الضغط داخل العين) والكاتاراكت (إعتام عدسة العين). من الممكن أن يقرر مقدم الرعاية الصحية الخاص بطفلك إلى ضرورة إجراء فحوصات للعين أثناء استعمال بلميريما معلق للاستخدام في جهاز الاستنشاق.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>ارتفاع أزيز بالصدر ناحية اليمين بعد</strong><strong> </strong><strong>استخدام بلميريما معلق للاستخدام في جهاز الاستنشاق</strong><strong>.&nbsp; </strong><strong>اصطحب معك دائمًا دواء موسع الشعب الهوائية الاستنشاقي سريع المفعول لعلاج حالات الأزيز المفاجئة</strong><strong>. </strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية أخرى محتملة:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الجهاز التنفسي: يمكن أن تشمل الأعراض على انسداد الأنف والتهاب بالأنف والحنجرة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيلان الأنف.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سعال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالات عدوى فيروسية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تهيج فيروسي والتهاب المعدة والأمعاء (التهابات المعدة والأمعاء). قد تشتمل أعراض التهابات المعدة والأمعاء على ما يلي: ألم في منطقة المعدة، إسهال، غثيان وقيء وفقدان الشهية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهابات الأذن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف الأنف.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب قاع العين (التهاب المُلْتَحِمَة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي.</p><p dir="RTL">أخبر الطبيب المعالج إذا كانت طفلك يعاني من أيّ آثار جانبية تزعجه أو تزعجها ولا تزول.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong><strong>:</strong></p><p dir="RTL">إذا عانيت من أية آثار جانبية، تحدَّث إلى الطبيب المعالج لك أو الصيدلي الخاص بك. ويشمل ذلك أية آثار جانبية مُحتمَلة غير مُدرجة في هذه النَّشرة. ويمكنك الإبلاغ عن الآثار الجانبية مباشرة عن طريق نظام الإبلاغ الوطني. يمكنك المساعدة في توفير معلومات إضافية حول أمان استخدام هذا الدواء من خلال إبلاغك عن الآثار الجانبية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <ul><li dir="RTL">لا يتم تخزينه في درجة حرارة اعلى من ٣٠ درجة مئوية، يحفظ بعيدا عن الضوء، ولا يجمد.</li><li dir="RTL">يُحفظ هذا الدواء بعيدًا عن رؤية ومتناول الأطفال.</li><li dir="RTL">لا تستعمل هذا الدَّواء بعد انتهاء تاريخ الصَّلاحية المدون على الملصق والعبوة الكرتونية بعد كلمة &quot;EXP&quot;. يُشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</li><li dir="RTL">لا تتخلص من الأدوية عن طريق إلقائها في مياه الصرف أو مع المخلفات المنزلية. استشر الصيدلي الخاص بك عن كيفية التَّخلص من الأدوية التي لم تَعُد تستخدمها، حيث تساعد هذه التدابير في الحفاظ على البيئة.</li><li dir="RTL">بعد الفتح لا يتم تخزينه في درجة حرارة اعلى من ٣٠ درجة مئوية ولا يجمد.</li><li dir="RTL">يمكن استخدام الظرف خلال ٣ شهور من فتحه.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>محتويات بلميريما</strong> <strong>المعلق للاستخدام في جهاز الاستنشاق</strong><strong>:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي بوديسونيد. تحتوي كل جرعة استنشاقية على 2 مللي لتر من المعلَّق على 0,25 مجم&nbsp;&nbsp; و0.5 مجم و1 مجم من بوديسونيد وفقًا لدستور الأدوية الأمريكي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي بولي سوربات 80 وكلوريد الصوديوم وايديتات ثنائي الصوديوم وستيرات الصوديوم وحمص ستريك أحادي الهيدرات وماء للحُقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>شكل بلميريما المعلق للاستخدام في جهاز الاستنشاق، ومحتويات العبوة:</strong></p><p dir="RTL">هذا الدواء معلق لونه أبيض مائل إلي الأصفر ومتجانس وجاف ويتم تعبئته كل 2 مللي لتر في عبوة جرعة استنشاقية معبئة ومغلفة بتقنية التعبئة والتغليف الأوتوماتيكية لإتاحة الفحص البصري.</p><p dir="RTL">تحتوي كل علبة كرتونية على 6 عبوات مجمعة بكل عبوة 5 جرعات استنشاقية مقدار كل جرعة 2 مللي لتر.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>تم التصنيع من قبل:</strong></p><p dir="RTL"><strong>Cipla Ltd</strong></p><p dir="RTL">l الوحدة ، القطعة 9 و 10 و 15 منطقة إندور الاقتصادیة الخاصة ، المرحلة الثانیة ، بیثامبور، مقاطعة - دار، مادیا برادیش ، الھند &ndash; 454775 (یُطلق علیه من الآن فصاعدًا اسم سیبلا إندور)</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>مالك حق التسويق</strong></p><p dir="RTL">شركة سدیر للأدویة</p><p dir="RTL">طریق الملك فھد - مبنى 8006 - الدور الرابع - الریاض &ndash; المملكة العربیة السعودیة</p><p dir="RTL">ھاتف: 0096611920001432</p><p dir="RTL">فاكس: 00966114668195</p><p dir="RTL">إيميل: info@sudairpharma.com</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تاریخ مراجعة النشرة :
أبريل 2021

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
PULMIREMA 0.25mg nebuliser suspension
PULMIREMA 0.5 mg nebuliser suspension
PULMIREMA 1.0mg Inebuliser suspension

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
PULMIREMA 0.25mg nebuliser suspension

Each respule of 2 mL suspension contains 0.25 mg budesonide USP.

PULMIREMA 0.5 mg nebuliser suspension

Each respule of 2 mL suspension contains 0.50 mg budesonide USP.

PULMIREMA 1.0mg Inebuliser suspension

Each respule of 2 ml suspension contains 1 mg budesonide USP. For
the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Nebuliser suspension.


A white to off white, homogeneous redispersible suspension filled in plastic ampoules. On visual
examination, there is no sign of physical damage or leakage

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>PULMIREMA nebuliser suspension is indicated for the maintenance treatment of asthma<br />and as prophylactic therapy in children 12 months to 8 years of age.</p><p>Limitations of use<br />PULMIREMA nebuliser suspension is not indicated for the relief of acute<br />bronchospasm.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>&nbsp;</p><p>The recommended starting dose and highest recommended dose of PULMIREMA, based on prior asthma therapy, are listed in the following table.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Previous Therapy</strong></p></td><td><p><strong>Recommended Starting Dose</strong></p></td><td><p><strong>Highest Recommended Dose</strong></p></td></tr><tr><td><p>&nbsp;</p><p>Bronchodilators alone</p></td><td><p>0.5 mg total daily dose administered either once daily</p><p>or twice daily in divided doses</p></td><td><p>&nbsp;</p><p>0.5 mg total daily dose</p></td></tr><tr><td><p>&nbsp;</p><p>Inhaled corticosteroids</p></td><td><p>0.5 mg total daily dose administered either once daily or twice daily in divided doses</p></td><td><p>&nbsp;</p><p>1 mg total daily dose</p></td></tr><tr><td><p>&nbsp;</p><p>Oral corticosteroids</p></td><td><p>1 mg total daily dose administered either as 0.5 mg</p><p>twice daily or 1 mg once daily</p></td><td><p>&nbsp;</p><p>1 mg total daily dose</p></td></tr></tbody></table><p>&nbsp;</p><p>Dosing recommendations based on previous therapy are as follows:</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bronchodilators alone: 0.5 mg once daily or 0.25 mg twice daily</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inhaled corticosteroids: 0.5 mg once daily or 0.25 mg twice daily up to 0.5 mg twice daily</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Oral corticosteroids: 0.5 mg twice daily or 1 mg once daily</p><p>&nbsp;</p><p>In symptomatic children not responding to non-steroidal therapy, a starting dose of 0.25 mg once daily may be considered. If once-daily treatment does not provide adequate control, the total daily dose should be increased and/or administered as a divided dose. In all patients, it is desirable to downward-titrate to the lowest effective dose once asthma stability is achieved.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>&nbsp;</p><p>For inhalation use only.</p><p>&nbsp;</p><p>PULMIREMA&nbsp; respules &nbsp;should &nbsp;be&nbsp;&nbsp; administered&nbsp;&nbsp; via&nbsp; jet&nbsp;&nbsp; nebulizer&nbsp;&nbsp; connected&nbsp;&nbsp; to an air compressor with an&nbsp; adequate&nbsp; air&nbsp; flow,&nbsp; equipped&nbsp; with&nbsp; a&nbsp; mouthpiece&nbsp; or suitable face mask. Ultrasonic nebulizers are not suitable for &nbsp;the &nbsp;adequate administration of PULMIREMA respules and, therefore, are NOT recommended.</p><p>The effects of mixing PULMIREMA respules&nbsp; with&nbsp; other&nbsp; nebulizable&nbsp; medications have not been adequately assessed. PULMIREMA respules should be administered separately in the nebulizer (see Patient information leaflet)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Local effects</u></p><p>In clinical trials with PULMIREMA, localized infections with <em>Candida albicans </em>occurred in the mouth and pharynx in some patients. The incidences of localized&nbsp; infections&nbsp; of <em>Candida albicans </em>were similar between the placebo and PULMIREMA treatment groups. If these infections develop, they may require treatment with appropriate local or systemic antifungal therapy and/or discontinuance of treatment with PULMIREMA. Patients should rinse the mouth after inhalation of PULMIREMA.</p><p>&nbsp;</p><p><u>Deterioration of disease and acute asthma episodes</u></p><p>&nbsp;</p><p>PULMIREMA is not a bronchodilator and is not indicated for the rapid relief of acute bronchospasm or other acute episodes of asthma.</p><p>&nbsp;</p><p>Patients should be instructed to contact their physician immediately if episodes of asthma not responsive to their usual doses of bronchodilators occur during the course of treatment with PULMIREMA. During such episodes, patients may require therapy with oral corticosteroids.</p><p>&nbsp;</p><p><u>Hypersensitivity reactions including anaphylaxis</u></p><p>&nbsp;</p><p>Hypersensitivity reactions including anaphylaxis, rash, contact dermatitis, urticaria, angioedema, and bronchospasm have been reported with use of &nbsp;PULMIREMA. Discontinue PULMIREMA if such reactions occur.</p><p>&nbsp;</p><p><u>Immunosuppression</u></p><p>&nbsp;</p><p>Patients who are on drugs that suppress the immune system are more susceptible to infection than healthy individuals. Chicken pox and measles, for example, can have a more serious or even fatal course in susceptible children or adults using corticosteroids. In children or adults who have not had these diseases, or been properly immunized, particular care should be taken to avoid exposure. How the dose, route, and duration of corticosteroid administration affect the risk of developing a disseminated infection is not known. The contribution of the underlying disease and/or prior corticosteroid treatment to the risk is also not known. If exposed to chicken pox, therapy with varicella zoster immune globulin (VZIG) or pooled intravenous immunoglobulin (IVIG), as appropriate, may be indicated. If exposed to measles, prophylaxis with pooled intramuscular immunoglobulin (IG) may be indicated (see the respective ssummary of product characteristicsf or complete VZIG and IG prescribing information). If chicken pox develops, treatment with antiviral agents may be considered.</p><p>&nbsp;</p><p>The clinical course of chicken pox or measles infection in patients on inhaled corticosteroids has not been studied. However, a clinical study has examined the immune responsiveness of asthma patients 12 months to 8 years of age who were treated with PULMIREMA. An open- label non-randomized clinical study examined the immune responsiveness of varicella vaccine in 243 asthma patients 12 months to 8 years of age who were treated with PULMIREMA 0.25 mg to 1 mg daily (n=151) or non-corticosteroid asthma therapy (n=92) (i.e., beta2agonists, leukotriene receptor antagonists, cromones). The percentage of patients developing a seroprotective antibody titer of &ge;5.0 (gpELISA value) in response to the vaccination was similar in patients treated with PULMIREMA (85%) compared to patients treated with non- corticosteroid asthma therapy (90%). No patient treated with PULMIREMA developed chicken pox as a result of vaccination.</p><p>&nbsp;</p><p>Inhaled corticosteroids should be used with caution, if at all, in patients with active or</p><p>&nbsp;</p><p>quiescent tuberculosis infection of the respiratory tract, untreated systemic fungal, bacterial, viral, or parasitic infections; or ocular herpes simplex.</p><p>&nbsp;</p><p><u>Transferring patients from systemic corticosteroid therapy</u></p><p>Particular care is needed for patients who are transferred from systemically active corticosteroids to inhaled corticosteroids because deaths due to adrenal insufficiency have occurred in asthmatic patients during and after transfer from systemic corticosteroids to less systemically available inhaled corticosteroids. After withdrawal from systemic corticosteroids, a number of months are required for recovery of hypothalamic-pituitary- adrenal (HPA)-axis function.</p><p>&nbsp;</p><p>Patients who have been previously maintained on 20 mg or more per day of prednisone (or its equivalent) may be most susceptible, particularly when their systemic corticosteroids have been almost completely withdrawn.</p><p>&nbsp;</p><p>During this period of HPA-axis suppression, patients may exhibit signs and symptoms of adrenal insufficiency when exposed to trauma, surgery, infection (particularly gastroenteritis) or other conditions associated with severe electrolyte loss. Although PULMIREMA may provide control of asthma symptoms during these episodes, in recommended doses it supplies less than normal physiological amounts of glucocorticosteroid systemically and does NOT provide the mineralocorticoid activity that is necessary for coping with these emergencies.</p><p>&nbsp;</p><p>During periods of stress or a severe asthma attack, patients who have been withdrawn from systemic corticosteroids should be instructed to resume oral corticosteroids (in large doses) immediately and to contact their physicians for further instructions. These patients should also be instructed to carry a medical identification card indicating that they may need supplementary systemic corticosteroids during periods of stress or a severe asthma attack.</p><p>&nbsp;</p><p>Patients requiring oral corticosteroids should be weaned slowly from systemic corticosteroid use after transferring to PULMIREMA. Initially, PULMIREMA should be used concurrently with the&nbsp; patient&rsquo;s &nbsp;usual &nbsp;maintenance &nbsp;dose &nbsp;of &nbsp;systemic &nbsp;corticosteroid. After approximately one week, gradual withdrawal of the systemic corticosteroid may be initiated by reducing the daily or alternate daily dose. Further incremental reductions may be made after an interval of one or two weeks, depending on the response of the patient. Generally, these decrements should not exceed 25% of the prednisone dose or its equivalent. A slow rate of withdrawal is strongly recommended.</p><p>&nbsp;</p><p>Lung function (FEV1 or AM PEF), beta-agonist use, and asthma symptoms should be carefully monitored during withdrawal of oral corticosteroids. In addition to monitoring asthma signs and symptoms, patients should be observed for signs and symptoms of adrenal insufficiency such as fatigue, lassitude, weakness, nausea and vomiting, and hypotension.</p><p>&nbsp;</p><p>Transfer of patients from systemic corticosteroid therapy to PULMIREMA may unmask allergic or other immunologic conditions previously suppressed by the systemic corticosteroid therapy, e.g., rhinitis, conjunctivitis, eosinophilic conditions, eczema, and arthritis.</p><p>&nbsp;</p><p>During withdrawal from oral corticosteroids, patients may experience symptoms of systemically active corticosteroid withdrawal (e.g., joint and/or muscular pain, lassitude, depression) despite maintenance or even improvement of respiratory function.</p><p>&nbsp;</p><p><u>Hypercorticism and adrenal suppression</u></p><p>PULMIREMA, will often help control asthma symptoms with less suppression of HPA function</p><p>&nbsp;</p><p>than therapeutically equivalent oral doses of prednisone. Since individual sensitivity to effects on cortisol production exists, physicians should consider this information when prescribing</p><p>&nbsp;</p><p>PULMIREMA. Because of the possibility of systemic absorption of inhaled corticosteroids, patients treated with PULMIREMA should be observed carefully for any evidence of systemic corticosteroid effects. Particular care should be taken in observing patients postoperatively or during periods of stress for evidence of inadequate adrenal response. &nbsp;It &nbsp;is&nbsp; &nbsp;possible&nbsp; &nbsp;that&nbsp; &nbsp;systemic&nbsp; &nbsp;corticosteroid&nbsp; &nbsp;effects&nbsp; &nbsp;such&nbsp; &nbsp;as hypercorticism,&nbsp;&nbsp; and&nbsp;&nbsp; adrenal&nbsp;&nbsp; suppression (including adrenal crisis) may appear in a small number&nbsp; of&nbsp; patients,&nbsp; particularly&nbsp; when PULMIREMA is administered at higher than recommended doses over prolonged periods of time.&nbsp; If&nbsp; such&nbsp; effects occur, the dosage of PULMIREMA should be reduced slowly, consistent with accepted procedures for tapering of systemic corticosteroids and for management of asthma.</p><p>&nbsp;</p><p><u>Reduction in bone mineral density</u></p><p>Decreases in bone mineral density (BMD) have been observed with long-term administration of products containing inhaled corticosteroids. The clinical significance of small changes in BMD with regard to long-term outcomes is unknown. Patients with major risk factors for&nbsp; decreased &nbsp;bone &nbsp;mineral &nbsp;content, &nbsp;such &nbsp;as &nbsp;prolonged &nbsp;immobilization,&nbsp;&nbsp; family history of osteoporosis, poor nutrition, or chronic use of drugs that can reduce bone mass&nbsp; (e.g.,&nbsp; anticonvulsants &nbsp;and &nbsp;corticosteroids), &nbsp;should &nbsp;be &nbsp;monitored &nbsp;and&nbsp;&nbsp; treated with established standards of care.</p><p>&nbsp;</p><p><u>Effects on growth</u></p><p>Orally inhaled corticosteroids, including PULMIREMA, may cause&nbsp; a&nbsp; reduction&nbsp; in growth velocity when administered to pediatric&nbsp; patients.&nbsp; Monitor&nbsp; the&nbsp; growth&nbsp; of pediatric patients receiving PULMIREMA &nbsp;routinely &nbsp;(e.g., &nbsp;via &nbsp;stadiometry). &nbsp;To minimize the systemic effects of orally inhaled corticosteroids, including budesonide respules, each patient should be titrated to his/her lowest effective dose (see section 5.1).</p><p>&nbsp;</p><p><u>Glaucoma and Cataracts</u></p><p>Glaucoma, increased intraocular pressure, and cataracts have been reported following the long-term administration of inhaled corticosteroids, including budesonide. Therefore, close monitoring is warranted in patients with a change in vision&nbsp; or&nbsp; with&nbsp; a&nbsp; history&nbsp; of increased intraocular pressure, glaucoma, and/or cataracts.</p><p>&nbsp;</p><p><u>Paradoxical bronchospasm and upper airway symptoms</u></p><p>As with other inhaled asthma medications, bronchospasm, with an immediate increase in wheezing, may occur after dosing. If acute bronchospasm occurs following dosing with&nbsp; &nbsp;PULMIREMA,&nbsp; &nbsp;it&nbsp; &nbsp;should&nbsp; &nbsp;be&nbsp; &nbsp;treated&nbsp; &nbsp;immediately&nbsp; &nbsp;with&nbsp;&nbsp;&nbsp; a&nbsp;&nbsp;&nbsp; fast-acting inhaled bronchodilator. Treatment with PULMIREMA should be discontinued and alternate therapy instituted.</p><p>&nbsp;</p><p><u>Eosinophilic conditions and Churg-Strauss Syndrome</u></p><p>In rare cases, patients on &nbsp;inhaled &nbsp;corticosteroids &nbsp;may &nbsp;present &nbsp;with &nbsp;systemic eosinophilic conditions. Some of these patients have clinical features of vasculitis consistent with Churg- Strauss syndrome, a condition that is often treated with systemic corticosteroids therapy. These events usually,&nbsp; but&nbsp; not&nbsp; always,&nbsp; have&nbsp; been&nbsp; associated with the reduction and/or withdrawal of oral corticosteroid therapy following the introduction of inhaled corticosteroids. Healthcare providers should be alert to eosinophilia, vasculitis rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy presenting in their patients. A causal relationship &nbsp;between PULMIREMA and these underlying conditions has not been established.</p><p>&nbsp;</p><p><u>Drug interactions with strong Cytochrome P450 3A4 inhibitors</u></p><p>Caution should be exercised when considering the coadministration of budesonide with ketoconazole, and other known strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin) because adverse effects related to increased systemic exposure to budesonide may occur (see sections 4.5 and 5.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The metabolism of PULMIREMA is primarily mediated by CYP3A4. Co-treatment with CYP3A inhibitors, e.g. itraconazole, ketoconazole, HIV protease inhibitors and cobicistat- containing products, are expected to increase the risk of systemic side effects (see Section 4.4 and Section 5.2).</p><p>&nbsp;</p><p>The combination of PULMIREMA with potent CYP3A inhibitors should be avoided unless the benefit outweighs the increased risk of systemic corticosteroid side effects, in which case patients should be monitored for systemic corticosteroid side effects. If PULMIREMA is co- administered with anti-fungals (such as itraconazole and ketoconazole), the period between treatments should be as long as possible. A reduction of the PULMIREMA dose could be considered.</p><p>&nbsp;</p><p>Limited data about this interaction for high-dose inhaled PULMIREMA indicate that marked increases in plasma levels (on average four-fold) may occur if itraconazole, 200 mg once daily, is administered concomitantly with inhaled PULMIREMA (single dose of 1000 &micro;g).</p><p>&nbsp;</p><p>Raised plasma concentrations of and enhanced effects of corticosteroids have been observed in women also treated with oestrogens and contraceptive steroids, but no effect has been observed with PULMIREMA and concomitant intake of low dose combination oral contraceptives.</p><p>&nbsp;</p><p>Because adrenal function may be suppressed, an ACTH stimulation test for diagnosing pituitary insufficiency might show false results (low values).</p><p>&nbsp;</p><p>Paediatric population</p><p>Interaction studies have only been performed in adults</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp; Pregnancy</p><p>Most results from prospective epidemiological studies and world-wide post-marketing data</p><p>have not been able to detect an increased risk for adverse effects for the foetus and newborn child from the use of inhaled PULMIREMA during pregnancy.</p><p>&nbsp;</p><p>In animal studies, glucocorticosteroids have been shown to induce malformations (see section 5.3). This is not likely to be relevant for humans given recommended doses, but therapy with inhaled PULMIREMA should be regularly reviewed and maintained at the lowest effective dose. It is important for both foetus and mother to maintain an adequate asthma treatment during pregnancy. As with other drugs administered during pregnancy, the benefit of the administration of PULMIREMA for the mother should be weighed against the risks to the foetus.</p><p>&nbsp;</p><p>Inhaled glucocorticosteroids should be considered in preference to oral glucocorticosteroids because of the lower systemic effects at the doses required to achieve similar pulmonary</p><p>&nbsp;</p><p>responses.</p><p>&nbsp;</p><p>Breast-feeding</p><p>PULMIREMA is excreted in breast milk. However, at therapeutic doses of PULMIREMA no effects on the suckling child are anticipated. PULMIREMA can be used during breast- feeding.</p><p>&nbsp;</p><p>Maintenance treatment with inhaled PULMIREMA (200 or 400 micrograms twice daily) in asthmatic nursing women results in negligible systemic exposure to PULMIREMA in breast- fed infants.</p><p>&nbsp;</p><p>In a pharmacokinetic study, the estimated daily infant dose was 0.3% of the daily maternal dose for both dose levels, and the average plasma concentration in infants was estimated to be 1/600th of the concentrations observed in maternal plasma, assuming complete infant oral bioavailability. PULMIREMA concentrations in infant plasma samples were all less than the limit of quantification.</p><p>&nbsp;</p><p>Based on data from inhaled PULMIREMA and the fact that PULMIREMA exhibits linear PK properties within the therapeutic dosage intervals after nasal, inhaled, oral and rectal administrations, at therapeutic doses of PULMIREMA, exposure to the breast-fed child is anticipated to be low.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>PULMIREMA respules has no or negligible&nbsp; influence&nbsp; on&nbsp; the&nbsp; ability to&nbsp; drive and use machines</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The following definitions apply to the incidence of undesirable effects: Frequencies are</p><p>defined as: very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to</p><p>&lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000).</p><p>Table 1 Adverse Drug Reactions (ADR) by System Organ Class (SOC) and Frequency</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>SOC</strong></p></td><td><p><strong>Frequency</strong></p></td><td><p><strong>Adverse Drug Reaction</strong></p></td></tr><tr><td><p>Infections and infestations</p></td><td><p>Common</p></td><td><p>Oropharyngeal candidiasis Pneumonia (in COPD patients)</p></td></tr><tr><td><p>Immune system disorders</p></td><td><p>Rare</p></td><td><p>Immediate and delayed hypersensitivity reactions* including rash, contact dermatitis, urticaria, angioedema and anaphylactic reaction</p></td></tr><tr><td><p>Endocrine disorders</p></td><td><p>Rare</p></td><td><p>Signs and symptoms of systemic corticosteroid effects, including adrenal suppression and growth retardation**</p></td></tr><tr><td rowspan="5"><p>Psychiatric disorders</p></td><td><p>Uncommon</p></td><td><p>Anxiety Depression</p></td></tr><tr><td rowspan="4"><p>Rare</p></td><td><p>Psychomotor hyperactivity</p></td></tr><tr><td><p>Sleep disorders</p></td></tr><tr><td><p>Aggression</p></td></tr><tr><td><p>Behavioural changes (predominantly in children)</p></td></tr><tr><td><p>Nervous system disorders</p></td><td><p>Uncommon</p></td><td><p>Tremor***</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0" style="width:1024px"><tbody><tr><td rowspan="3" style="width:171px"><p>Eye disorders</p></td><td rowspan="2" style="width:84px"><p>Uncommon</p></td><td style="width:766px"><p>Cataract</p></td></tr><tr><td style="width:766px"><p>Vision, blurred (see also section 4.4)</p></td></tr><tr><td style="width:84px"><p>Unknown</p></td><td style="width:766px"><p>Glaucoma</p></td></tr><tr><td rowspan="6" style="width:171px"><p>Respiratory, thoracic and mediastinal disorders</p></td><td rowspan="3" style="width:84px"><p>Common</p></td><td style="width:766px"><p>Cough</p></td></tr><tr><td style="width:766px"><p>Hoarseness</p></td></tr><tr><td style="width:766px"><p>Throat irritation</p></td></tr><tr><td rowspan="3" style="width:84px"><p>Rare</p></td><td style="width:766px"><p>Bronchospasm</p></td></tr><tr><td style="width:766px"><p>Dysphonia</p></td></tr><tr><td style="width:766px"><p>Hoarseness****</p></td></tr><tr><td style="width:171px"><p>Skin and subcutaneous tissue disorders</p></td><td style="width:84px"><p>Rare</p></td><td style="width:766px"><p>Bruising</p></td></tr><tr><td style="width:171px"><p>Musculoskeletal and connective tissue disorders</p></td><td style="width:84px"><p>Uncommon</p></td><td style="width:766px"><p>Muscle spasm</p></td></tr></tbody></table><p>&nbsp;</p><p>* refer to Description of selected adverse reactions; facial skin irritation below</p><p>** refer to Paediatric population, below</p><p>*** based on frequency reported in clinical trials</p><p>**** rare in children</p><p>Occasionally, signs or symptoms of systemic glucocorticosteroid-side effects may occur with inhaled glucocorticosteroids, probably depending on dose, exposure time, concomitant and previous corticosteroid exposure, and individual sensitivity (see section 4.4).</p><p>Description of selected adverse reactions</p><p>The candida infection in the oropharynx is due to drug deposition. Advising the patient to rinse the mouth out with water after each dosing will minimise the risk.</p><p>As with other inhalation therapy, paradoxical bronchospasm may occur in very rare cases (see Section 4.4).</p><p>Facial skin irritation, as an example of a hypersensitivity reaction, has occurred in some cases when a nebuliser with a face mask has been used. To prevent irritation, the facial skin should be washed with water after use of the face mask.</p><p>In placebo-controlled studies, cataract was also uncommonly reported in the placebo group.</p><p>As per the reference, Clinical trials with 13119 patients on inhaled PULMIREMA and 7278 patients on placebo have been pooled. The frequency of anxiety was 0.52% on inhaled PULMIREMA and 0.63% on placebo; that of depression was 0.67% on inhaled PULMIREMA and 1.15% on placebo.</p><p>Paediatric population</p><p>Due to the risk of growth retardation in the paediatric population, growth should be monitored as described in section 4.4.</p><p><u>Reporting of suspected adverse reactions</u></p><p>&nbsp;</p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions by submitting complelete form to npc.drug@sfda.gov.sa.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>PULMIREMA Respules contains 0.1 mg/ml disodium edetate which has been shown to cause bronchoconstriction at levels above 1.2 mg/ml. Acute overdosage with PULMIREMA Respules, even in excessive doses, is not expected to be a clinical problem.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Mechanism of action</u></p><p>PULMIREMA is an anti-inflammatory corticosteroid that &nbsp;exhibits &nbsp;potent glucocorticoid activity and weak mineralocorticoid activity. In standard <em>in vitro </em>and animal models, PULMIREMA has approximately a 200-fold higher affinity for the glucocorticoid receptor and a 1000-fold higher topical anti-inflammatory potency than cortisol (rat croton oil ear edema assay). As a measure of systemic activity, PULMIREMA is 40 times more potent than cortisol when administered subcutaneously and 25 times more potent when administered orally in the rat thymus involution assay. The clinical significance of these findings is unknown.</p><p>&nbsp;</p><p>The &nbsp;activity &nbsp;of &nbsp;PULMIREMA &nbsp;respules &nbsp;is &nbsp;due&nbsp; &nbsp;to&nbsp; &nbsp;the&nbsp; &nbsp;parent&nbsp; &nbsp;drug, PULMIREMA. In glucocorticoid receptor affinity studies, the 22R&nbsp; form&nbsp; was&nbsp; two times as active as the 22S epimer. <em>In vitro </em>studies indicated that the two forms of PULMIREMA do not interconvert.</p><p>&nbsp;</p><p>The precise mechanism of corticosteroid actions on inflammation in asthma is not well known. Inflammation is an important component in the pathogenesis of asthma. Corticosteroids have been shown to have a wide range of inhibitory activities against multiple&nbsp;&nbsp; cell&nbsp;&nbsp; types&nbsp;&nbsp; (e.g.,&nbsp;&nbsp; mast&nbsp;&nbsp; cells,&nbsp;&nbsp; eosinophils,&nbsp;&nbsp; neutrophils,&nbsp;&nbsp; macrophages, and lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, and cytokines) involved in allergic-and non-allergic- mediated inflammation. The anti- inflammatory actions of corticosteroids may contribute to their efficacy in asthma.</p><p>&nbsp;</p><p>Studies in asthmatic patients have shown a favorable ratio between topical anti- inflammatory activities and systemic corticosteroid effects over a wide dose range of inhaled &nbsp;PULMIREMA &nbsp;in &nbsp;a &nbsp;variety &nbsp;of &nbsp;formulations &nbsp;and&nbsp;&nbsp; delivery&nbsp;&nbsp; systems including an inhalation-driven, multi-dose dry powder inhaler and the inhalation suspension for&nbsp; nebulization.&nbsp; This&nbsp; is&nbsp; explained&nbsp; by&nbsp; a&nbsp; combination&nbsp; of&nbsp; a&nbsp; relatively high local anti-inflammatory effect, extensive first pass hepatic degradation of orally absorbed drug (85-95%) and the low potency of metabolites (see below).</p><p>&nbsp;</p><p><u>Pharmacodynamics</u></p><p>The therapeutic effects of conventional doses of orally inhaled PULMIREMA are largely explained by its direct local action on the respiratory tract. To confirm that systemic absorption is not a significant factor in the clinical efficacy of inhaled PULMIREMA,&nbsp;&nbsp; a&nbsp;&nbsp; clinical&nbsp; &nbsp;study&nbsp; &nbsp;in&nbsp; &nbsp;adult&nbsp; &nbsp;patients&nbsp;&nbsp; &nbsp;with&nbsp;&nbsp; &nbsp;asthma&nbsp;&nbsp; &nbsp;was performed comparing 400 mcg&nbsp; PULMIREMA&nbsp; administered&nbsp; via&nbsp; a&nbsp; pressurized metered dose inhaler with a tube spacer to 1400 mcg of oral PULMIREMA&nbsp; and placebo. The study demonstrated&nbsp; the&nbsp; efficacy&nbsp; of inhaled&nbsp; PULMIREMA &nbsp;but &nbsp;not orally &nbsp;administered &nbsp;PULMIREMA,&nbsp; &nbsp;even&nbsp; &nbsp;though&nbsp; &nbsp;systemic&nbsp;&nbsp; PULMIREMA exposure was comparable&nbsp; for&nbsp; both&nbsp; treatments,&nbsp; indicating&nbsp; that&nbsp; the&nbsp; inhaled treatment is working locally in the lung. Thus, the therapeutic effect of conventional doses of orally inhaled PULMIREMA are largely explained by its direct action&nbsp; on&nbsp; the respiratory tract.</p><p>&nbsp;</p><p>Improvement in the control of asthma symptoms following inhalation of budesonide respules can occur within 2-8 days of beginning treatment, although maximum benefit may not be achieved for 4-6 weeks.</p><p>&nbsp;</p><p>PULMIREMA administered via a dry powder inhaler has been shown&nbsp; in&nbsp; various challenge models (including histamine, methacholine, sodium metabisulfite, &nbsp;and adenosine monophosphate) to decrease bronchial hyperresponsiveness in asthmatic patients. The clinical relevance of these models is not certain.</p><p>&nbsp;</p><p>Pre-treatment with PULMIREMA administered as 1600 mcg daily (800 mcg twice daily) via a dry powder inhaler for 2 weeks reduced the acute (early-phase reaction) and delayed (late- phase reaction) decrease in FEV1 following inhaled allergen challenge.</p><p>&nbsp;</p><p><em><u>HPA axis effects</u></em></p><p>The effects of PULMIREMA respules on the hypothalamic-pituitary-adrenal (HPA) axis were studied in three, 12week, double-blind, placebo-controlled studies in 293 pediatric patients, 6 months to 8 years of age, with persistent asthma. For most patients, the ability to increase cortisol production in response to stress, as assessed by the short cosyntropin (ACTH) stimulation test, remained intact with PULMIREMA respules treatment at recommended doses. In the subgroup of children age 6 months to 2 years (n=21) receiving a total daily dose of PULMIREMA respules equivalent to 0.25 mg (n=5), 0.5 mg (n=5), 1 mg (n=8), or placebo (n=3), the mean change from baseline in ACTH-stimulated cortisol levels showed a decline in peak stimulated cortisol at 12 weeks compared to an increase in the placebo group. These mean differences were not statistically significant compared to placebo. Another 12-week study in 141 &nbsp;pediatric &nbsp;patients &nbsp;6&nbsp;&nbsp; to&nbsp;&nbsp; 12&nbsp;&nbsp; months&nbsp;&nbsp; of&nbsp;&nbsp; age with mild to &nbsp;moderate &nbsp;asthma &nbsp;or recurrent/persistent wheezing was conducted. All patients were randomized to receive either 0.5 mg or 1 mg of PULMIREMA respules or placebo once daily. A total of 28, 17, and 31 patients in the PULMIREMA respules 0.5 mg, 1 mg, and placebo arms respectively, had an evaluation of serum cortisol levels post-ACTH stimulation both at baseline and at the end of the study. The mean change from baseline to Week 12 ACTH-stimulated minus basal plasma cortisol levels did not indicate adrenal suppression in patients treated with PULMIREMA respules versus placebo. However, 7 patients in this study (4 of whom received budesonide respules 0.5 mg, 2 of whom received PULMIREMA respules 1 mg and 1 of whom received placebo) showed a shift from normal baseline stimulated cortisol level (&ge;500 nmol/L) to a subnormal level (&lt;500 nmol/L) at Week</p><p>12. In 4 of these patients receiving PULMIREMA respules, the cortisol values were near the cutoff value of 500 nmol/L.</p><p>&nbsp;</p><p>The effects of PULMIREMA respules at doses of 0.5 mg twice daily, and 1 mg and 2 mg twice daily (2 times and 4 times the highest recommended total daily dose, respectively) on 24-hour urinary cortisol excretion were studied in 18 patients between 6 to 15 years of age with persistent asthma in a cross-over study design (4 weeks of treatment per dose level). There was a dose-related decrease in urinary cortisol excretion at 2 and 4 times the recommended daily dose. The two higher doses of PULMIREMA respules (1 and 2 mg twice daily) showed statistically significantly reduced (4352%) urinary cortisol excretion compared to the run-in period. The highest recommended dose of PULMIREMA respules, 1 mg total daily dose, did not show statistically significantly reduced urinary cortisol excretion compared to the run-in period.</p><p>&nbsp;</p><p>PULMIREMA respules, like other&nbsp; inhaled&nbsp; corticosteroid&nbsp; products,&nbsp; may&nbsp; impact&nbsp; the HPA axis, especially in susceptible individuals, in younger children, and in patients given high doses for prolonged periods (see section 4.4).</p><p>&nbsp;</p><p><u>Clinical studies</u></p><p>Three double-blind, placebo-controlled, parallel group, randomized U.S. clinical trials of 12- weeks duration each were conducted in 1018 pediatric patients, 6 months to 8 years of age, 657 males and 361 females (798 Caucasians, 140 Blacks, 56 Hispanics, 3 Asians, 21 Others) with persistent asthma of varying disease duration (2 to 107 months) and severity. Doses of</p><p>0.25 mg, 0.5 mg, and 1 mg administered either once or twice daily were compared to placebo to provide information about appropriate dosing to cover a range of asthma severity. A Pari- LC-Jet &nbsp;Plus &nbsp;Nebulizer &nbsp;(with &nbsp;a &nbsp;face &nbsp;mask &nbsp;or &nbsp;mouthpiece) &nbsp;connected &nbsp;to&nbsp; a&nbsp;&nbsp; Pari Master compressor was used to deliver PULMIREMA respules to patients in the 3 U.S. controlled clinical&nbsp; trials. &nbsp;The &nbsp;co-primary &nbsp;endpoints &nbsp;were &nbsp;nighttime &nbsp;and &nbsp;daytime asthma symptom scores (0-3 scale). Improvements were addressed in terms&nbsp; of&nbsp; the primary efficacy variables of changes from&nbsp; baseline&nbsp; to&nbsp; the&nbsp; double-blind&nbsp; treatment period in nighttime and daytime asthma symptom scores (scale 0-3) as recorded in the patient diaries. Baseline was defined as the mean of the last seven days prior to randomization).&nbsp; The&nbsp; double-blind treatment period was defined as the mean over 12- week treatment period. Each of the five doses discussed below were studied in one or two, but not all three of the U.S. studies.</p><p>&nbsp;</p><p>Results of the 3 controlled clinical trials for recommended dosages of PULMIREMA inhalation suspension (0.25 mg to 0.5 mg once or twice daily, or 1 mg once daily, up to a total daily dose of &nbsp;1 &nbsp;mg) &nbsp;in &nbsp;946 &nbsp;patients, &nbsp;12 &nbsp;months &nbsp;to &nbsp;8 &nbsp;years &nbsp;of &nbsp;age,&nbsp;&nbsp; are presented below. &nbsp;Statistically &nbsp;significant &nbsp;decreases &nbsp;in &nbsp;night &nbsp;time &nbsp;and &nbsp;daytime symptom scores of asthma were observed at PULMIREMA respules doses of 0.25&nbsp; mg once daily (one study), 0.25 mg twice daily, and 0.5 mg&nbsp; twice&nbsp; daily&nbsp; compared&nbsp; to placebo. Use of PULMIREMA respules resulted in statistically significant decreases in either night time or daytime symptom scores, but not both, at doses of 1 mg once daily, and</p><p>0.5 mg once daily (one study). Symptom reduction in&nbsp; response&nbsp; to&nbsp; PULMIREMA respules occurred across gender and age. Statistically significant reductions in the need for bronchodilator therapy were also observed at all the doses of PULMIREMA respules studied.</p><p>&nbsp;</p><p>Improvements in lung function were associated with PULMIREMA respules in the subgroup of patients capable of &nbsp;performing &nbsp;lung &nbsp;function &nbsp;testing. &nbsp;Statistically significant increases were seen in FEV1 [PULMIREMA respules 0.5 mg once daily and 1 mg once daily (one study); 0.5 mg twice daily] and morning PEF [PULMIREMA respules 1 mg once daily (one study); 0.25 mg twice daily; 0.5 mg twice daily] compared to placebo.</p><p>&nbsp;</p><p>A numerical reduction in night time and daytime symptom scores (0-3 scale) of asthma was observed within 2-8 days, although maximum benefit was not achieved for 4-6 weeks after starting treatment. The reduction in night time and daytime asthma symptom scores was maintained throughout the 12 weeks of the double-blind trials.</p><p>&nbsp;</p><p><em><u>Patients not receiving inhaled corticosteroid therapy</u></em></p><p>The efficacy of PULMIREMA respules at doses of 0.25 mg, 0.5 mg, and 1 mg once daily was evaluated &nbsp;in &nbsp;344&nbsp;&nbsp; pediatric&nbsp;&nbsp; patients,&nbsp;&nbsp; 12&nbsp;&nbsp; months&nbsp;&nbsp; to&nbsp;&nbsp; 8&nbsp;&nbsp; years&nbsp;&nbsp; of&nbsp;&nbsp; age,&nbsp;&nbsp; with mild &nbsp;to&nbsp; moderate &nbsp;persistent&nbsp; asthma&nbsp; (mean&nbsp; baseline&nbsp; night&nbsp; time&nbsp; asthma&nbsp; symptom scores of the treatment groups ranged from 1.07 to 1.34) who were not well controlled by bronchodilators alone. The changes from baseline to Weeks 0-12 in night time asthma symptom scores are shown in Figure 1.</p><p>&nbsp;</p><p>Night time asthma symptom scores&nbsp; &nbsp;showed&nbsp; &nbsp;statistically&nbsp; &nbsp;significant&nbsp; &nbsp;decreases&nbsp; &nbsp;in the patients treated with PULMIREMA respules compared to placebo. Similar decreases were also observed for daytime asthma symptom scores.</p><p>&nbsp;</p><p>Changes from baseline to the double-blind phase for the PULMIREMA treatment groups compared to placebo were made using analysis of variance techniques. The model included terms for the respective changes from baseline as the dependent variable and terms for treatment, center and treatment by center interaction as exploratory variables (see Figures 1- 3).</p><p><img alt="" width="513" height="267" src="data:image/jpeg;base64,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" /></p><p>p-value &ndash; 0.25 mg: 0.001, 0.5 mg: 0.010, 1.0 mg: 0.009</p><p>&nbsp;</p><p><strong>Figure 1: A </strong>12-Week Trial in Pediatric Patients Not on Inhaled Corticosteroid Therapy Prior to Study Entry. Nighttime Asthma Change from Baseline</p><p>&nbsp;</p><p><em><u>Patients previously maintained on inhaled corticosteroids</u></em></p><p>The efficacy of PULMIREMA respules at doses of 0.25 mg and 0.5 mg twice daily was evaluated in 133 pediatric asthma patients, 4&nbsp; &nbsp;to&nbsp; &nbsp;8&nbsp; &nbsp;years&nbsp; &nbsp;of&nbsp; &nbsp;age,&nbsp; &nbsp;previously maintained on inhaled corticosteroids (mean FEV1 79.5% predicted; mean baseline nighttime asthma symptom scores of the treatment groups ranged from 1.04 to 1.18; mean baseline dose of beclomethasone dipropionate of 265 mcg/day, ranging between</p><p>42 to 1008 mcg/day; mean baseline dose of triamcinolone acetonide of 572 mcg/day, ranging between 200 to 1200 mcg/day). The changes from baseline to Weeks 0-12 in nighttime asthma symptom scores are shown in Figure 2. Nighttime asthma symptom scores showed statistically significant decrease in patients treated with PULMIREMA respules compared to placebo. Similar decreases were also&nbsp;&nbsp; observed&nbsp;&nbsp; for&nbsp;&nbsp; daytime asthma symptom scores.</p><p>&nbsp;</p><p>Statistically significant increases in FEV1 compared to placebo were observed with PULMIREMA respules at a dose of 0.5 mg twice daily and in morning PEF for both doses (0.25 mg and 0.5 mg twice daily).</p><p><img alt="" width="500" height="262" src="data:image/jpeg;base64,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" /></p><p>p-values: 0.25 mg: 0.022, 0.5 mg: 0.021</p><p>&nbsp;</p><p><strong>Figure 2: </strong>A 12-Week Trial in Pediatric Patients Previously Maintained on Inhaled Corticosteroid Therapy Prior to Study Entry. Nighttime Asthma Change from&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Baseline</p><p>&nbsp;</p><p><em><u>Patients receiving once-daily or twice-daily dosing</u></em></p><p><em>&nbsp;</em></p><p>The efficacy of budesonide respules at doses of 0.25 mg once daily, 0.25 mg twice daily, 0.5 mg twice daily, and 1 mg once daily, was evaluated in 469 pediatric patients 12 months to 8 years of age (mean baseline nighttime asthma symptom scores of the treatment groups ranged from</p><p>1.13 to 1.31). Approximately 70% were not previously receiving inhaled corticosteroids. The changes from baseline to Weeks 0-12 in nighttime asthma symptom scores are shown in Figure</p><p>3. budesonide respules at doses of 0.25 mg and 0.5 mg twice daily, and 1 mg once daily, demonstrated statistically significant decreases in nighttime asthma symptom scores compared to placebo. Similar decreases were also observed for daytime asthma symptom scores.</p><p>&nbsp;</p><p>PULMIREMA respules at a dose of 0.5 mg twice daily resulted in statistically significant increases compared to placebo in FEV1, and at doses of 0.25 mg and 0.5 mg twice daily and&nbsp; &nbsp;1 mg once daily statistically significant increases in morning PEF.</p><p>&nbsp;</p><p>The evidence supports the efficacy of the same nominal dose of PULMIREMA respules administered on either a once-daily or twice-daily schedule. However, when all measures are considered together, the evidence is stronger for twice-daily dosing (see section 4.2)</p><p><img alt="" width="348" height="179" src="data:image/jpeg;base64,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" /></p><p>&nbsp;</p><p>p-values: 0.25 mg qd: 0.121, 0.25 mg bid: &lt;0.001, 0.5 mg bid: 0.003, 1.0 mg qd: 0.005</p><p>&nbsp;</p><p><strong>Figure 3</strong>: A 12-Week Trial in Pediatric Patients Either Maintained on Bronchodilators Alone or Inhaled Corticosteroid Therapy Prior to Study Entry. Nighttime Asthma Change from Baseline</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>In asthmatic children 4-6 years of age, the total absolute bioavailability (i.e., lung + oral) following administration of PULMIREMA respules via jet nebulizer was approximately 6% of the labeled dose.</p><p>&nbsp;</p><p>In children, a peak plasma concentration of 2.6 nmol/L was obtained approximately 20 minutes after nebulization of a 1 mg dose. Systemic exposure, as measured by AUC and Cmax, is similar for young children and adults after inhalation of the same dose of PULMIREMA respules.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>In asthmatic children 4-6 years of age, the volume of distribution at steady-state of PULMIREMA was 3 L/kg, approximately the &nbsp;same &nbsp;as &nbsp;in &nbsp;healthy &nbsp;adults. PULMIREMA is 85-90% bound to plasma proteins, the degree&nbsp; of&nbsp; binding&nbsp; being constant over the concentration range (1-100 nmol/L) achieved with, and exceeding, recommended doses. PULMIREMA showed little or no binding to corticosteroid-binding globulin. PULMIREMA rapidly equilibrated with red blood cells in a concentration independent manner with a blood/plasma ratio of about 0.8.</p><p>&nbsp;</p><p><u>Metabolism</u></p><p><em>In vitro </em>studies with human liver homogenates have shown that PULMIREMA is rapidly and extensively metabolized. Two major metabolites formed via cytochrome P450 (CYP) isoenzyme 3A4 (CYP3A4) catalyzed biotransformation have been isolated and identified as 16&alpha;-hydroxyprednisolone and 6&beta;-hydroxybudesonide. The corticosteroid activity of each of these two metabolites is less than 1% of that of the parent compound. No qualitative difference between the <em>in vitro </em>and <em>in vivo </em>metabolic patterns has been&nbsp; detected. Negligible metabolic inactivation was observed in human lung and serum preparations.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>PULMIREMA is primarily cleared by the liver. PULMIREMA is excreted in urine and feces in the form of metabolites. In adults, approximately 60% of an intravenous radiolabeled dose was recovered in the urine. No unchanged PULMIREMA was detected in the urine.</p><p>&nbsp;</p><p>In asthmatic children 4-6 years of age, the terminal half-life of PULMIREMA after nebulization is 2.3 hours, and the systemic clearance is 0.5 L/min, &nbsp;which &nbsp;is approximately 50% greater than in healthy adults after adjustment for differences in weight.</p><p>&nbsp;</p><p><u>Special populations</u></p><p>No differences in pharmacokinetics due to race, gender, or age have been identified.</p><p>&nbsp;</p><p><em><u>Hepatic impairment</u></em></p><p>Reduced liver function may affect the elimination of corticosteroids. The pharmacokinetics of budesonide were affected by&nbsp; compromised&nbsp; liver&nbsp; function&nbsp; as&nbsp; evidenced&nbsp; by&nbsp; a doubled systemic availability&nbsp; after&nbsp; oral&nbsp; ingestion.&nbsp; The&nbsp; intravenous&nbsp; pharmacokinetics of PULMIREMA were, however, similar in cirrhotic patients and in healthy adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Preclinical data revealed no special hazard for humans in the therapeutic dose range based on studies of chronic toxicity, genotoxicity and carcinogenicity.</p><p>&nbsp;</p><p>Glucocorticoids, including PULMIREMA, have produced teratogenic effects in animals, including cleft palate and skeletal abnormalities. Similar effects are considered unlikely to occur in humans at the recommended dose levels.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>excipients </strong></p><p>Polysorbate 80, Sodium chloride, Edetate disodium,</p><p>Sodium citrate,</p><p>Citric acid monohydrate, Water for injection.</p><p>Nitrogen</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 Months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C, Protect from light, Do not freeze After opening Do not store above 30&deg;C, Dont Freeze.</p><p>Store the Respules in the foil envelope to protect them from light. Units should be stored in an upright position and should be protected from freezing.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Carton containing 6 combi pack having 5 respules of 2 ml each.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sudair Pharma Company (SPC)
King Fahad road, Building 911- The First Round Riyadh, Saudi Arabia
Tel: +966-11-920001432
Fax: +966-11-4668195
Email: info@sudairpharma.com
Mailing: P.O. Box 19047 Riyadh, Saudi Arabia

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sep. 2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>